Alpha-glucosidase inhibitor

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Alpha-glucosidase inhibitors (AGIs) are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of carbohydrates (such as starch and table sugar). Carbohydrates are normally converted into simple sugars (monosaccharides) by alpha-glucosidase enzymes present on cells lining the intestine, enabling monosaccharides to be absorbed through the intestine. Hence, alpha-glucosidase inhibitors reduce the impact of dietary carbohydrates on blood sugar.

Examples and differences[edit]

Examples of alpha-glucosidase inhibitors include:

Even though the drugs have a similar mechanism of action, there are subtle differences between acarbose and miglitol. Acarbose is an oligosaccharide, whereas miglitol resembles a monosaccharide. Miglitol is fairly well absorbed by the body, as opposed to acarbose. Moreover, acarbose inhibits pancreatic alpha-amylase in addition to alpha-glucosidase.

Natural alpha glucosidase inhibitors[edit]

There are a large number of natural products with alpha-glucosidase inhibitor action.[1][2]

For example, research has shown the culinary mushroom Maitake (Grifola frondosa) has a hypoglycemic effect.[3][4][5][6][7][8] The reason Maitake lowers blood sugar is because the mushroom naturally contains an alpha glucosidase inhibitor.[9] Another plant attracting a lot of attention is Salacia oblonga. /[citation needed]

Clinical use[edit]

Alpha-glucosidase inhibitors are used to establish greater glycemic control over hyperglycemia in diabetes mellitus type 2, particularly with regard to postprandial hyperglycemia. They may be used as monotherapy in conjunction with an appropriate diabetic diet and exercise, or they may be used in conjunction with other anti-diabetic drugs.

In patients with diabetes mellitus type 1, Alpha-glucosidase inhibitors use has not been officially approved by the Food and Drug Administration but some data exists on the effectiveness in this population, showing potential benefits weighted against an increased risk of hypoglycemia.[10]

Mechanism of action[edit]

Alpha-glucosidase inhibitors are saccharides that act as competitive inhibitors of enzymes needed to digest carbohydrates: specifically alpha-glucosidase enzymes in the brush border of the small intestines. The membrane-bound intestinal alpha-glucosidases hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the small intestine.

Acarbose also blocks pancreatic alpha-amylase in addition to inhibiting membrane-bound alpha-glucosidases. Pancreatic alpha-amylase hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine.

Inhibition of these enzyme systems reduces the rate of digestion of carbohydrates. Less glucose is absorbed because the carbohydrates are not broken down into glucose molecules. In diabetic patients, the short-term effect of these drugs therapies is to decrease current blood glucose levels: the long-term effect is a small reduction in hemoglobin A1c level.[11]


Since alpha-glucosidase inhibitors are competitive inhibitors of digestive enzymes, they must be taken at the start of main meals to have maximal effect. Their effects on blood sugar levels following meals will depend on the amount of complex carbohydrates in the meal.

Side effects and precautions[edit]

Since alpha-glucosidase inhibitors prevent the degradation of complex carbohydrates into glucose, the carbohydrates will remain in the intestine. In the colon, bacteria will digest the complex carbohydrates, thereby causing gastrointestinal side effects such as flatulence and diarrhea. Since these effects are dose-related, it is generally advised to start with a low dose and gradually increase the dose to the desired amount. Pneumatosis cystoides intestinalis is another reported side effect.[citation needed] If a patient using an alpha-glucosidase inhibitor suffers from an episode of hypoglycemia, the patient should eat something containing monosaccharides, such as glucose tablets. Since the drug will prevent the digestion of polysaccharides (or non-monosaccharides), non-monosaccharide foods may not effectively reverse a hypoglycemic episode in a patient taking an alpha-glucosidase inhibitor.[citation needed]

See also[edit]


  1. ^ Benalla, Wafaa; Bellahcen, Said; Bnouham, Mohamed (2010). "Antidiabetic Medicinal Plants as a Source of Alpha Glucosidase Inhibitors". Current Diabetes Reviews. 6 (4): 247–54. doi:10.2174/157339910791658826. PMID 20522017.
  2. ^ Ji, Fang; Xiao, Guochun; Dong, Li; Ma, Zijiao; Ni, Jingman (2010). 药用植物来源的α-葡萄糖苷酶抑制剂研究进展 [Development of α-glucosidase inhibitor from medicinal herbs]. China Journal of Chinese Materia Medica (in Chinese). 35 (12): 1633–40. doi:10.4268/cjcmm20101229. PMID 20815224.
  3. ^ Konno, S.; Tortorelis, D. G.; Fullerton, S. A.; Samadi, A. A.; Hettiarachchi, J.; Tazaki, H. (2001). "A possible hypoglycaemic effect of maitake mushroom on Type 2 diabetic patients". Diabetic Medicine. 18 (12): 1010. doi:10.1046/j.1464-5491.2001.00532-5.x. PMID 11903406.
  4. ^ Hong, Lei; Xun, Ma; Wutong, Wu (2007). "Anti-diabetic effect of an α-glucan from fruit body of maitake (Grifola frondosa) on KK-Ay mice". Journal of Pharmacy and Pharmacology. 59 (4): 575–82. doi:10.1211/jpp.59.4.0013. PMID 17430642.
  5. ^ Kubo, Keiko; Aoki, Hisao; Nanba, Hiroaki (1994). "Anti-diabetic Activity Present in the Fruit Body of Grifola frondosa (Maitake). I". Biological & Pharmaceutical Bulletin. 17 (8): 1106–10. doi:10.1248/bpb.17.1106. PMID 7820117.
  6. ^ Lo, Hui-Chen; Hsu, Tai-Hao; Chen, Ching-Yi (2008). "Submerged Culture Mycelium and Broth of Grifola frondosa Improve Glycemic Responses in Diabetic Rats". The American Journal of Chinese Medicine. 36 (2): 265–85. doi:10.1142/S0192415X0800576X. PMID 18457360.
  7. ^ Manohar, V.; Talpur, N. A.; Echard, B. W.; Lieberman, S.; Preuss, H. G. (2002). "Effects of a water-soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK mice". Diabetes, Obesity and Metabolism. 4 (1): 43–8. doi:10.1046/j.1463-1326.2002.00180.x. PMID 11874441.
  8. ^ Horio, Hiroyuki; Ohtsuru, Masaru (2001). "Maitake (Grifola frondosa) Improve Glucose Tolerance of Experimental Diabetic Rats". Journal of Nutritional Science and Vitaminology. 47 (1): 57–63. doi:10.3177/jnsv.47.57. PMID 11349892.
  9. ^ Matsuura, Hideyuki; Asakawa, Chikako; Kurimoto, Masanori; Mizutani, Junya (2002). "α-Glucosidase Inhibitor from the Seeds of Balsam Pear (Momordica charantia) and the Fruit Bodies of Grifola frondosa". Bioscience, Biotechnology, and Biochemistry. 66 (7): 1576–8. doi:10.1271/bbb.66.1576. PMID 12224646.
  10. ^ Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy: Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors. Michelle DeGeeter, PharmD, CDE, Bobbie Williamson, PharmD, BCACP, CDE. Journal of Pharmacy Practice Vol 29, Issue 2, pp. 144 - 159. First Published October 13, 2014
  11. ^ Venable, Samantha J.; Aschenbrenner, Diane S. (2006). Drug Therapy In Nursing. Hagerstown, MD: Lippincott Williams & Wilkins. ISBN 0-7817-4839-9.[page needed]